Conversion total hip arthroplasty (THA) after previous intertrochanteric (IT) hip fracture is a unique operation that is different from the routine primary total hip arthroplasty (THA) done for osteoarthritis or femoral head necrosis. Conversion THAs are similar to revision THAs with regard to complexity, technical challenges, implant costs, and perioperative complications. A literature review was performed with specific focus on the surgical techniques, patient outcomes, and financial burdens of conversion THAs after IT fracture treatment with either a sliding compression hip screw with side plate (SSP), or a cephalomedullary nail (CMN). The reported data demonstrated similar technical challenges regardless of the method of the index treatment of the IT fracture. The surgeon must plan and be prepared for more difficult and extensile exposure, available instruments for the hardware removal, altered proximal femoral geometry, and available implant inventory for the reconstruction. The outcomes are consistent with higher rates of instability and infection in the conversion THAs compared with primary THAs. There is no significant difference in the clinical outcomes of conversion THAs following either SSP or CMN. Overall, conversion THAs pose greater technical challenges. The clinical outcomes of conversion THAs remain inferior to the primary THAs. The complications and patient functional outcomes are similar to those following revision THAs.
Category: opioid consumption Introduction/Purpose: The expanding opioid crisis has forced orthopedic surgeons to evaluate their prescribing practices, yet there remains limited evidence to guide providers in achieving safe and effective postoperative analgesia. Our goal was to prospectively evaluate opioid consumption following outpatient foot and ankle surgery and determine predictors of increased narcotic usage. Methods: We prospectively enrolled adult patients scheduled for outpatient foot and ankle surgery and conducted phone and in- person interviews postoperatively to determine pain level, number of pills consumed, satisfaction with pain control, and whether other analgesic medication was used. Interviews were performed at four separate time points: 5 days, 10 days, 2 weeks, and 6 weeks following surgery. Additional data collected included age, gender, payer status, education level, preoperative pain level, procedure performed, whether opioid pain medication had been used by the patient in the 12 months preceding surgery, and the amount of narcotic prescribed postoperatively. Results: Complete data was available for 52 patients (median age, 42 years). The median number of opioids prescribed postoperatively was 45 pills (337.5 morphine milligram equivalents (MMEs)). A refill narcotic prescription was provided for 36.5% of patients. The number of opioid pills consumed following surgery ranged from 0 to 120 (median, 40 pills). Forty-six percent of patients had discontinued the use of opioids by post-op day 10 and 86.5% by post-op day 20. Increased pre-operative pain level (p = 0.02) and an increased quantity of pills prescribed at the first prescription (<0.0001) were significantly associated with increased narcotic consumption. Eighteen (39.1%) patients filled a narcotic prescription in the 12 months prior to surgery, however, narcotic use prior to surgery did not significantly increase total opioid consumption. Conclusion: We found that the median number of opioids consumed following outpatient foot and ankle surgery was 40 pills. Nearly 90% of patients had discontinued narcotic use by 20 days postoperatively. Pre-operative pain level and the number of pills provided at the first prescription were predictive of increased narcotic usage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.